• Explore /
  • Poster
  • / Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.

Abstract Poster

Authors

null

Zev A. Wainberg

School of Medicine, University of California, Los Angeles, CA

Zev A. Wainberg , Kohei Shitara , Eric Van Cutsem , Lucjan Wyrwicz , Keun Wook Lee , Iveta Kudaba , Marcelo Garrido , Hyun Cheol Cheol Chung , Jeeyun Lee , Hugo Raul Castro-Salguero , Wasat Mansoor , Maria Ignez Braghiroli , Nina Karaseva , Eray Goekkurt , Hironaga Satake , Joseph Chao , Uma Kher , Sukrut Shah , Pooja Bhagia , Josep Tabernero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02494583

DOI

10.1200/JCO.2022.40.4_suppl.243

Abstract #

243

Poster Bd #

E1

Abstract Disclosures

Similar Posters

First Author: Hironaga Satake

First Author: Zev A. Wainberg

First Author: Sun Young Rha

First Author: Josep Tabernero